Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | KD033, a PDL1-1L15 bispecific molecule for the treatment of cancer

Jason Luke • 14 Nov 2021
SITC 2021
General Antibodies KD033

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, describes the mechanism of action of the PDL1-IL15 bispecific molecule, KD033. Early dose-escalation clinical trial data of PDL1-IL15 have demonstrated responses in the form of fevers and chills and even disease regression in some patients. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Jason Luke

0:48
Final analysis of distant metastasis-free survival in the KEYNOTE-716 study
Jason Luke • 2 Jun 2023
0:33
KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanoma
Jason Luke • 2 Jun 2023
0:44
Novel therapeutic options for PD-1 refractory melanoma
Jason Luke • 2 Jun 2023
0:22
Who will benefit the most from adjuvant IO in melanoma?
Jason Luke • 2 Jun 2023

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals